Rupatadine
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP-mediated |
| Elimination half-life | 5.9 hours |
| Excretion | Fecal (60.9%) and renal (34.6%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H26ClN3 |
| Molar mass | 415.958 g/mol |
Overview
Rupatadine is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Ruptatadine is marketed by Panacea-Biotech under the trade name Ralif. Ralif is approved for the treatment of allergic rhinitis.
External links
Categories:
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- H1 receptor antagonists